Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus ANCEF IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN DEXTROSE 5 IN PLASTIC CONTAINER versus ANCEF IN PLASTIC CONTAINER.
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER vs ANCEF IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
None Documented
None Documented
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic